Document:

Exhibit 4.2

 

SHARE PURCHASE AGREEMENT

 

THIS SHARE PURCHASE AGREEMENT (this “Agreement”), is
made as of this 25 day of February, 2018, by and between NeuroSense Therapeutics Ltd., a company registered under the laws of the
State of Israel, having its principal place of business at [   ], Israel (the “Company”), and the
investors listed under Exhibit A attached hereto (the “Investors”).

 

WITNESSETH:

 

WHEREAS, the Company desires to sell to
the Investors and the Investors desire to purchase from the Company, on terms and for consideration hereinafter provided, such amount
of ordinary shares of the Company, nominal value NIS 0.01 each, (the “Purchased Shares”), at a price per share of US
$20, in accordance with the amounts and aggregate purchase prices per each Investor listed in the attached Exhibit A.

 

NOW, THEREFORE, in consideration of the
promises and the mutual covenants set forth herein, the parties hereto agree as follows.

 

		1.	Purchase and Sale of Shares

 

Upon the terms and subject to the conditions contained
in this Agreement, each Investor agrees to purchase the Purchased Shares from the Company and the Company agrees to sell the Purchased
Shares to each Investor at the Closing (as hereinafter defined).

 

		2.	Payment

 

Each Investor shall pay the Company the aggregate
purchase price for the Purchased Shares being acquired by such Investor at the Closing, as follows:

 

Account Name: NeuroSense Therapeutics Ltd.

Name of the Bank: [    ] Bank

Address of the Bank: [    ]

Branch no.: [    ]

Account number: [    ]

IBAN: [    ]

 

The Purchase Price will be paid in New Israeli
Shekels.

 

		3.	The Closing

 

3.1. The
closing of the purchase and sale of the Purchased Shares shall take place at such time and place as the Company shall agree to with each
specific Investor (the “Closing”).

 

    

     

    

 

3.2. At
each Closing:

 

		(i)	The Investor shall transfer to the Company the aggregate purchase price for the Purchased Shares being
acquired by such Investor; and

 

		(ii)	The Company shall deliver to the Investor a share certificate in the name of the Investor representing
the Investor’s Purchased Shares.

 

		4.	The Company’s Representation

 

The Company hereby represents and warrants to
each Investors that the sale, conveyance, transfer, assignment and delivery of the Purchased Shares by the Company to each Investor as
contemplated by this Agreement, will transfer to the Investors, as of the Closing, legal and valid title to the Purchased Shares, free
and clear of all claims, liens, charges, security interests and other encumbrances of any nature.

 

		5.	Investors’ Representation

 

Each Investor represents and warrants to the Company
that such Investor is acquiring the Purchased Shares for investment for the Investor’s own account and that the Investor has experience
in investing in securities of companies such as the Company. Each Investor approves that such Investor is able to bear the economic risk
of the investment and is capable of evaluating the merits and risk in investing in the Purchased Shares pursuant to this Agreement.

 

		6.	Further Assurances

 

The Company and each of the Investors agree to
do such further acts and things and to execute, acknowledge and deliver such further assignments, agreements, instruments and other documents
as the Investors or the Company reasonably may request, from time to time, to effectuate the sale of the Purchased Shares to the Investors
hereunder and to effectuate the purposes and all of the other terms and provisions of this Agreement.

 

		7.	Notices

 

All notices or other communications hereunder
shall be in writing and shall be deemed to have been duly given and delivered one (1) business day after it is delivered personally, by
messenger or three (3) business days after mailing, if sent by certified mail, return receipt requested, in all cases addressed to the
party for whom intended at its address set forth below:

 

If to the Company:

 

NeuroSense Therapeutics Ltd.

[    ], Israel

Attn: Alon Ben-Noon, CEO

 

If to the Investors: to the
addresses provided for in Exhibit A.

 

or to such other address as such party shall have
designated by a notice given in accordance herewith.

 

    2

     

    

 

		8.	Successors and Assigns; Assignment

 

All covenants, promises and agreements by or on
behalf of the parties contained in this Agreement, shall be binding on and inure to the benefit of the parties hereto and their respective
heirs, legal representatives, successors and assigns; provided, however, that nothing in this Agreement, express or implied, shall confer
on the Company or the Investors the right to assign or transfer any of its rights or delegate any of its respective payment obligations
hereunder at any time, whether prior to or after the Closing.

 

		9.	Amendments, Supplements, Waivers

 

This Agreement constitute the full and entire
understanding and agreement between the parties with regard to the subject matters hereof anti thereof and any other written or oral agreement
relating to the subject matter hereof existing between the parties are expressly canceled. Any term of this Agreement may be amended only
with the written consent of the Company and each of the Investors. The observance of any term hereof may be waived (either prospectively
or retroactively and either generally or in a particular instance) only with the written consent of the party against such waiver is sought.

 

		10.	Applicable Law

 

This Agreement shall be governed by and construed
according to the laws of the State of Israel, without regard to the conflict of laws provisions thereof The parties hereby irrevocably
and unconditionally submit to the exclusive jurisdiction of courts in Tel-Aviv in respect of any matter arising in connection with this
Agreement.

 

		11.	Entire Agreement; Survival

 

This Agreement sets forth the entire agreement
of the parties hereto with regard to the subject matter hereof and supersedes and replaces all prior agreements, understandings and representations,
oral or written, with regard to such matters. The representations, warranties covenants and agreements contained in this Agreement shall
survive the execution and delivery of this Agreement and the Closing.

 

		12.	Severability

 

If any term or provision of this Agreement shall
be held to be illegal, invalid or unenforceable under applicable law, it shall not affect the continued legality, validity and enforceability
of each remaining teen and provision hereof, each of which shall continue in full force and effect.

 

		13.	Counterparts

 

This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original and enforceable against the parties actually executing such counterpart, and all
of which together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the parties hereto
have caused this Agreement to be duly executed as of the date first above written.

 

	NeuroSense Therapeutics Ltd.	 	Yossi Gross
	 	 	 
	By:	 	 	By:	 
	Name:	Alon Ben-Noon	 	 
	Title:	CEO	 	 
	 	 	Erwin Gross
	 	 	 
	 	 	By:	 

 

    3

     

    

 

EXHIBIT A

 

INVESTORS AND INVESTMENT AMOUNTS

 

	Name of Investor	 	Address	 	 	Purchase Price	 	 	No. of Ordinary Shares	 
	Yossi Gross	 	 	[     ]	 	 	$	10,000	 	 	 	500	 
	Erwin Gross	 	 	[     ]	 	 	$	10,000	 	 	 	500	 
	Total	 	 	 	 	 	$	20,000	 	 	 	1,000	 

 

 

4Exhibit
4.3

 

THIS
INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED,
PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT OR AN EXEMPTION THEREFROM.

 

NEUROSENSE
Therapeutics LTD.1

 

SAFE

 

(Simple
Agreement for Future Equity)

 

THIS
CERTIFIES THAT in exchange for the payment by [__] (the “Investor”) of USD $[__] (the “Purchase Amount”)
on or about [__], NeuroSense Therapeutics Ltd., a limited liability company incorporated and existing under the laws of the State of
Israel (the “Company”), hereby issues to the Investor the right to certain shares of the Company, subject to the terms
set forth below.

 

1. Events.

 

(a) Equity Financing. If there is an Equity Financing before the expiration or termination of this instrument, the Company will automatically
issue to the Investor a number of Ordinary Shares equal to the Purchase Amount divided by the Safe Price. [If there is an equity financing
on the Company, in which the Company issues shares, that does not qualify as Equity Financing (a “Non qualifying EF”),
each of the Company and the Investor, by the delivery of a written notice to that effect to the other Party, shall have the right to
issue or force the Company to issue, as applicable, a number of Ordinary Shares equal to the Purchase Amount divided by the price per
share of the Non Qualifying EF.]

 

In
connection with the issuance of Ordinary Shares by the Company to the Investor pursuant to this Section ‎1(a), the Investor
will be obligated to execute and deliver to the Company all transaction documents related to the Equity Financing.

 

(b) Liquidity Event. If there is a Liquidity Event before the expiration or termination of this instrument, the Investor will automatically
receive from the Company a number of Ordinary Shares equal to the Purchase Amount divided by the Liquidity Price.

 

(c) Dissolution Event. If there is a Dissolution Event before this instrument expires or terminates, the Company will pay an amount
equal to the Purchase Amount, due and payable to the Investor immediately prior to, or concurrent with, the consummation of the Dissolution Event. The Purchase Amount,
as determined in good faith by the Company’s board of directors, shall be paid from the funds, if any, available for distribution
upon a Dissolution Event pro rata among the other shareholders and investors of the Company.

 

(d) Termination. This instrument will expire and terminate (without relieving the Company of any obligations arising from a prior
breach of or non-compliance with this instrument) upon either (i) the issuance of shares to the Investor pursuant to Section ‎1(a)
or Section ‎1(b); or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to Section
‎1(c).

 

2. Definitions.

 

“Change
of Control” means (i) any merger, reorganization or consolidation of the Company with or into another entity, or the acquisition
of the Company by means of any transaction or series of related transactions, following which the existing shareholders of the Company
as of immediately prior to such transaction or series of related transactions hold less than fifty percent (50%) of the voting power
of the surviving or acquiring entity or less than fifty percent (50%) of the issued and outstanding share capital of the surviving or
acquiring entity; (ii) a sale of all or substantially all of the assets of the Company (including, for this purpose, the grant of an
exclusive license to all or substantially all of the intellectual property rights of the Company), in a single transaction or a series
of related transactions; or (iii) any other transaction or series of related transactions in which more than fifty percent (50%) of the
outstanding share capital of the Company following such transaction or series of related transactions is held by a person or entity or
group of persons or entities (related contractually or otherwise), other than existing shareholders of the Company as of immediately
prior to such transaction or series of related transactions.

 

 

1
The bracketed language is included in some, but not all, of the SAFE Agreements.

 

    Page 1 of 5

     

    

 

“Company Capitalization” means
the sum, as of immediately prior to the Equity Financing or Liquidity Event, as applicable, of: (a) all of the Company’s issued
and outstanding shares (on an as-converted basis), assuming exercise or conversion of all outstanding vested and unvested options, warrants,
and other convertible securities, but excluding (i) this instrument, (ii) all other Safes, and (iii) convertible promissory notes; and
(b) all Ordinary Shares reserved and available for future grant under any equity incentive or similar plan of the Company, and/or any
equity incentive or similar plan to be created or increased in connection with the Equity Financing.

 

“Distribution”
means the transfer to holders of shares of the Company, by reason of their ownership thereof, of cash or other property without consideration
whether by way of dividend or otherwise, other than dividends on Ordinary Shares payable in Ordinary Shares, or the purchase or redemption
of Ordinary Shares by the Company or its subsidiaries, if any, for cash or property other than: (a) repurchases of Ordinary Shares
held by employees, officers, directors or consultants of the Company or its subsidiaries pursuant to an agreement providing, as applicable,
a right of first refusal or a right to repurchase shares upon termination of such service provider’s employment or services; or
(b) repurchases of shares of the Company in connection with the settlement of disputes with any shareholder.

 

“Dissolution
Event” means (a) a voluntary termination of operations, (b) a general assignment for the benefit of the Company’s creditors,
or (c) any other liquidation, dissolution or winding up of the Company (excluding a Liquidity Event), whether voluntary or involuntary.

 

“Equity
Financing” means a bona fide transaction or series of transactions with the principal purpose of raising capital in a minimum
amount of USD $[2,000,000][5,000,000], pursuant to which the Company issues and sells shares at a fixed pre-money valuation.

 

“Equity
Financing Valuation” means the Company’s valuation which the shares at an Equity Financing were issued, which shall not
be lower than Company valuation of $25,000,000.

 

“Initial
Public Offering” means the closing of the Company’s first firm commitment underwritten initial public offering of Ordinary
Shares.

 

“Liquidity
Event” means a Change of Control or an Initial Public Offering.

 

“Liquidity
Price” means the price per share equal to the Company’s valuation at the time of the Liquidity Event, multiplied by 80%
and divided by the Company Capitalization, which shall not be lower than Company valuation of $25,000,000.

 

“Ordinary
Shares” means ordinary shares of the Company, par value NIS 0.001 each.

 

“Safe”
means an instrument containing a future right to shares of the Company, similar in form and content to this instrument, purchased by
investors for the purpose of funding the Company’s business operations.

 

“Safe
Price” means the price per share equal to 80% of the Equity Financing Valuation.

 

3. Company Representations.

 

(a) The Company is a limited liability company duly organized and validly existing under the laws of the State of Israel, and has the power
and authority to own, lease, and operate its properties and carry on its business as now conducted.

 

(b) The execution, delivery, and performance by the Company of this instrument is within the power of the Company and, other than with respect
to the actions to be taken when equity is to be issued to the Investor, has been duly authorized by all necessary actions on the part
of the Company.

 

(c) This instrument constitutes a legal, valid, and binding obligation of the Company, enforceable against the Company in accordance with
its terms, except as limited by bankruptcy, insolvency, or other laws of general application relating to or affecting the enforcement
of creditors’ rights generally and general principles of equity. To the knowledge of the Company, it is not in violation of (i)
its current articles of association, (ii) any material law or regulation applicable to the Company, or (iii) any material indenture or
contract to which the Company is a party or by which it is bound, where, in each case, such violation or default, individually, or together
with all such violations or defaults, could reasonably be expected to have a material adverse effect on the Company.

 

    Page 2 of 5

     

    

 

(d) The performance and consummation of the transactions contemplated by this instrument do not and will not: (i) violate any material
judgment, law, or regulation applicable to the Company; (ii) result in the acceleration of any material indenture or contract to
which the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any lien upon any property,
asset, or revenue of the Company or the suspension, forfeiture, or nonrenewal of any material permit, license, or authorization applicable
to the Company, its business or operations.

 

(e) No consents or approvals are required in connection with the performance of this instrument, other than: (i) the Company’s corporate
approvals, including for the authorization of shares issuable pursuant to Section ‎1; and (ii) any qualifications or filings
under applicable securities laws.

 

(f) To its knowledge, the Company owns or possesses (or can obtain on commercially reasonable terms) sufficient legal rights to all patents,
trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, processes, and other intellectual property
rights necessary for its business as now conducted and as currently proposed to be conducted, without any conflict with, or infringement
of, the rights of others.

 

4. Investor Representations.

 

(a) The Investor has full legal capacity, power, and authority to execute and deliver this instrument and to perform its obligations hereunder.
This instrument constitutes valid and binding obligation of the Investor, enforceable in accordance with its terms, except as limited
by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally
and general principles of equity.

 

(b) The Investor is an accredited investor as such term is defined in Rule 501 of Regulation D under the Securities Act. The Investor
has been advised that this instrument and the underlying securities have not been registered under the Securities Act, or any state securities
laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless
an exemption from such registration requirements is available. The Investor is purchasing this instrument and the securities to be acquired
by the Investor hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection
with, the distribution thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same. The Investor has such knowledge and experience in financial and business matters that the Investor is capable of evaluating
the merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Investor’s financial
condition, and is able to bear the economic risk of such investment for an indefinite period of time.

 

(c) The Investor has been afforded the opportunity to ask questions concerning the business and financial condition, operations and prospects
of the Company and concerning the terms and conditions of this instrument, has asked such questions as it desired to ask, and has been
provided with answers to such questions to its full satisfaction.

 

(d) The Investor understands that no public market now exists for the shares underlying this instrument, and that the Company has made no
assurances that a public market will ever exist for such shares.

 

    Page 3 of 5

     

    

 

5. Miscellaneous.

 

(a) [The Investor hereby agrees that in the event of any underwritten public offering of Ordinary Shares, including an IPO, pursuant to an
effective registration statement filed under the Securities Act of 1933, as amended (the “Securities Act”), Investor
shall not affect any public sale or distribution of Ordinary Shares or of any securities convertible into or exchangeable or exercisable
for Ordinary Shares, during the period beginning 14 days prior to the expected date of “pricing” of such public offering
and continuing for a period not to exceed 180 days after the date of the final prospectus (or prospectus supplement if the offering is
made pursuant to a “shelf” registration statement) as may be established by the underwriter(s) for such public offering.
If and to the extent requested by the managing underwriter(s), Investor agrees to execute an agreement to the foregoing effect with the
underwriter(s) for such public offering on such terms as the managing underwriter(s) shall reasonably request (with such modification
as reasonably requested by such managing underwriter(s) to take into consideration then existing rules of an applicable securities exchange
regarding research analyst publications).]

 

(b) Any provision of this instrument may be amended, waived, or modified only upon the written consent of the Company and the Investor.

 

(c) This instrument constitutes the full and entire understanding and agreement between the parties hereto with respect to the subject matter
hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties hereto are expressly
canceled.

 

(d) All notices and other communications given or made pursuant to this instrument shall be in writing and shall be deemed effectively given
upon the earlier of: (i) actual receipt; (ii) personal delivery; (iii) transmission, if transmitted by electronic mail or facsimile during
normal business hours of the recipient, or, if not sent during normal business hours, the recipient’s next business day, provided
that, in either case, the transmitting party shall not have received a bounce-back or other delivery failure notice; (iv) five (5)
days after having been sent by registered or certified mail, return receipt requested, postage prepaid; and (v) one (1) business day
after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification
of receipt. All communications hereunder shall be given to the respective party using the contact details in such party’s signature
block below, or using such contact details as such party shall subsequently provide by written notice in accordance with this Section
‎‎‎5(e).

 

(e) The provisions hereof shall inure to the benefit of, and be binding upon, the respective successors, assigns, heirs, executors, and administrators
of the parties hereto. Neither this instrument nor the rights contained herein may be assigned, by operation of law or otherwise, by
either party without the prior written consent of the other party; provided, however, that this instrument and/or the rights
contained herein may be assigned without the Company’s consent by the Investor to any other entity who directly or indirectly,
controls, is controlled by or is under common control with the Investor; and provided, further, that the Company may assign
this instrument in whole, without the consent of the Investor, in connection with a reincorporation to change the Company’s domicile.

 

(f) In the event any one or more of the provisions of this instrument is for any reason held to be invalid, illegal, or unenforceable, in
whole or in part or in any respect, or in the event that any one or more of the provisions of this instrument operate or would prospectively
operate to invalidate this instrument, then and in any such event, such provision(s) only will be deemed null and void and will not affect
any other provision of this instrument and the remaining provisions of this instrument will remain operative and in full force and effect
and will not be affected, prejudiced, or disturbed thereby.

 

(g) All rights and obligations hereunder will be governed by the laws of the State of Israel, without regard to the conflicts of law provisions
of such jurisdiction. The parties submit to the exclusive jurisdiction of the competent courts of Tel Aviv-Jaffa in any dispute arising
out of this instrument.

 

(h) This instrument may be executed in any number of counterparts, each of which shall be deemed an original and enforceable against the
party actually executing such counterpart, and all of which together shall constitute one and the same instrument. Executed counterparts
delivered via any means of electronic transmission shall be deemed as originals.

 

(i)
The Investor shall cause the transfer the Purchase Price to the Company, within no longer than five (5) days after the execution of this
instrument, by wire transfer to the Company’s bank account.

 

[Signature
page follows] 

 

    Page 4 of 5

     

    

 

IN
WITNESS WHEREOF, the undersigned have caused this instrument to be duly executed and delivered.

 

	NEUROSENSE Therapeutics LTD.	 
	 	 	 
	By: 	                                                   	 
	Name:  	Alon Ben-Noon	 
	Title: 	CEO	 
	 	 	 
	Address: Medinat Hayehudim St. 85, Herzeliya, 4676670, Israel
	Email: 	 
	 	 	 
	[__]	 	 
	 	 	 
	By: 	 	 
	 	 	 
	Address: [__]	 
	Email: [__]	 

 

[Signature
page to Simple Agreement for Future Equity]

 

 

Page 5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]